In April 2020, CHAI and Unitaid launched an Early Market Access Vehicle (EMAV) to catalyze procurement and introduction of the VISITECT® CD4 Advanced Disease test by providing it at no cost to interested Ministries of Health and implementing partners. By the end of 2022, over 200,000 tests were been delivered to partners across 13 countries. This document summarizes the challenges, lessons learned, and recommendations from this implementation.